| Characteristics . | CREDENCE . | CANVAS . | DECLARE-TIMI . | EMPA-REG . | VERTIS . | DAPA-CKD . |
|---|---|---|---|---|---|---|
| SGLT-2 inhibitor | Canagliflozin | Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin | Dapagliflozin |
| Year of publication | 2019 | 2017 | 2019 | 2015 | 2020 | 2020 |
| Median follow-up period (years) | 2.6 | 2.4 | 4.2 | 3.1 | 3.0 | 2.4 |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 63.0 (9.2) | 63.3 (8.3) | 63.9 (6.8) | 63.1 (8.6) | 64.4 (8.1) | 61.8 (12.1) |
| Men, n (%) | 2907 (66.1) | 6509 (64.2) | 10 738 (62.6) | 5016 (71.5) | 5769 (70.0) | 2879 (66.9) |
| Race, n (%) | ||||||
| White | 2931 (66.6) | 7944 (78.3) | 13 653 (79.6) | 5081 (72.4) | 7240 (87.8) | 2290 (53.2) |
| Asian | 877 (19.9) | 1284 (12.7) | 2303 (13.4) | 1517 (21.6) | 498 (6.0) | 1467 (34.1) |
| Black | 224 (5.1) | 336 (3.3) | 603 (3.5) | 357 (5.1) | 235 (2.8) | 191 (4.4) |
| Other/missing | 369 (8.4) | 578 (5.7) | 601 (3.5) | 65 (0.9) | 273 (3.3) | 356 (8.3) |
| Medical history | ||||||
| CVD, n (%) | 2220 (50.4) | 6656 (65.6) | 6974 (40.6) | 7020 (100) | 8246 (100) | 1610 (37.4) |
| CHF, n (%) | 652 (14.8) | 1461 (14.4) | 1724 (10.0) | 706 (10.1) | 1958 (23.7) | 468 (10.9) |
| CKD, n (%) | 2631 (59.8) | 2039 (20.1) | 1265 (7.4) | 1819 (25.9) | 1807 (21.9) | 4304 (100) |
| DM, n (%) | 4401 (100) | 10 142 (100) | 17 160 (100) | 7020 (100) | 8246 (100) | 2906 (67.5) |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 4395 (99.9) | 8116 (80.0) | 13 950 (81.3) | 5666 (80.7) | 6686 (81.1) | 4224 (98.1) |
| Beta blocker, n (%) | 1770 (40.2) | 5421 (53.5) | 9030 (52.6) | 4554 (64.9) | 5692 (69.0) | — |
| Statin/ezetimibe, n (%) | 3036 (69.0) | 7599 (74.9) | 12868 (75.0) | 5403 (77.0) | 6790 (82.3) | 2794 (64.9) |
| Characteristics | EMPEROR REDUCED | SOLOIST-WHF | EMPEROR-PRESERVED | SCORED | DAPA-HF | |
| SGLT-2 inhibitor | Empagliflozin | Sotagliflozin | Empagliflozin | Sotagliflozin | Dapagliflozin | |
| Year of publication | 2020 | 2021 | 2021 | 2021 | 2019 | |
| Median follow-up period, (years) | 1.3 | 0.8 | 2.2 | 1.3 | 1.5 | |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 66.9 (11) | 69.5 | 71.8 (9.3) | 69 | 66.4 (10.9) | |
| Men, n (%) | 2837 (76.1) | 810 (66.2) | 3312 (55.3) | 5830 (55.1) | 3635 (76.6) | |
| Race, n (%) | ||||||
| White | 2629 (70.5) | 1139 (93.2) | 4542 (75.6) | 8749 (82.7) | 3333 (70.3) | |
| Asian | 672 (18.0) | 15 (1.2) | 824 (13.8) | 682 (6.4) | 1116 (23.5) | |
| Black | 257 (6.9) | 50 (4.1) | 258 (4.3) | 364 (3.4) | 226 (4.8) | |
| Other/missing | 172 (4.6) | 18 (1.5) | 364 (6.1) | 789 (7.5) | 69 (1.5) | |
| Medical history | ||||||
| CVD, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 9381 (88.6) | 4744 (100) | |
| CHF, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 3283 (31.0) | 4744 (100) | |
| CKD, n (%) | 1799 (48.2) | — | 2988 (49.9) | 10 584 (100) | 1926 (40.6) | |
| DM, n (%) | 1856 (49.8) | 1222 (100) | 2938 (49.1) | 10 584 (100) | 1983 (41.8) | |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 2600 (69.7) | 1010 (82.7) | 4832 (80.7) | 9365 (88.5) | 3968 (83.6) | |
| Beta blocker, n (%) | 3533 (94.7) | 1125 (92.1) | 5167 (86.3) | 6616 (62.5) | 4558 (96.1) | |
| Statin/ezetimibe, n (%) | — | — | 4131 (70.0) | — | — |
| Characteristics . | CREDENCE . | CANVAS . | DECLARE-TIMI . | EMPA-REG . | VERTIS . | DAPA-CKD . |
|---|---|---|---|---|---|---|
| SGLT-2 inhibitor | Canagliflozin | Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin | Dapagliflozin |
| Year of publication | 2019 | 2017 | 2019 | 2015 | 2020 | 2020 |
| Median follow-up period (years) | 2.6 | 2.4 | 4.2 | 3.1 | 3.0 | 2.4 |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 63.0 (9.2) | 63.3 (8.3) | 63.9 (6.8) | 63.1 (8.6) | 64.4 (8.1) | 61.8 (12.1) |
| Men, n (%) | 2907 (66.1) | 6509 (64.2) | 10 738 (62.6) | 5016 (71.5) | 5769 (70.0) | 2879 (66.9) |
| Race, n (%) | ||||||
| White | 2931 (66.6) | 7944 (78.3) | 13 653 (79.6) | 5081 (72.4) | 7240 (87.8) | 2290 (53.2) |
| Asian | 877 (19.9) | 1284 (12.7) | 2303 (13.4) | 1517 (21.6) | 498 (6.0) | 1467 (34.1) |
| Black | 224 (5.1) | 336 (3.3) | 603 (3.5) | 357 (5.1) | 235 (2.8) | 191 (4.4) |
| Other/missing | 369 (8.4) | 578 (5.7) | 601 (3.5) | 65 (0.9) | 273 (3.3) | 356 (8.3) |
| Medical history | ||||||
| CVD, n (%) | 2220 (50.4) | 6656 (65.6) | 6974 (40.6) | 7020 (100) | 8246 (100) | 1610 (37.4) |
| CHF, n (%) | 652 (14.8) | 1461 (14.4) | 1724 (10.0) | 706 (10.1) | 1958 (23.7) | 468 (10.9) |
| CKD, n (%) | 2631 (59.8) | 2039 (20.1) | 1265 (7.4) | 1819 (25.9) | 1807 (21.9) | 4304 (100) |
| DM, n (%) | 4401 (100) | 10 142 (100) | 17 160 (100) | 7020 (100) | 8246 (100) | 2906 (67.5) |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 4395 (99.9) | 8116 (80.0) | 13 950 (81.3) | 5666 (80.7) | 6686 (81.1) | 4224 (98.1) |
| Beta blocker, n (%) | 1770 (40.2) | 5421 (53.5) | 9030 (52.6) | 4554 (64.9) | 5692 (69.0) | — |
| Statin/ezetimibe, n (%) | 3036 (69.0) | 7599 (74.9) | 12868 (75.0) | 5403 (77.0) | 6790 (82.3) | 2794 (64.9) |
| Characteristics | EMPEROR REDUCED | SOLOIST-WHF | EMPEROR-PRESERVED | SCORED | DAPA-HF | |
| SGLT-2 inhibitor | Empagliflozin | Sotagliflozin | Empagliflozin | Sotagliflozin | Dapagliflozin | |
| Year of publication | 2020 | 2021 | 2021 | 2021 | 2019 | |
| Median follow-up period, (years) | 1.3 | 0.8 | 2.2 | 1.3 | 1.5 | |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 66.9 (11) | 69.5 | 71.8 (9.3) | 69 | 66.4 (10.9) | |
| Men, n (%) | 2837 (76.1) | 810 (66.2) | 3312 (55.3) | 5830 (55.1) | 3635 (76.6) | |
| Race, n (%) | ||||||
| White | 2629 (70.5) | 1139 (93.2) | 4542 (75.6) | 8749 (82.7) | 3333 (70.3) | |
| Asian | 672 (18.0) | 15 (1.2) | 824 (13.8) | 682 (6.4) | 1116 (23.5) | |
| Black | 257 (6.9) | 50 (4.1) | 258 (4.3) | 364 (3.4) | 226 (4.8) | |
| Other/missing | 172 (4.6) | 18 (1.5) | 364 (6.1) | 789 (7.5) | 69 (1.5) | |
| Medical history | ||||||
| CVD, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 9381 (88.6) | 4744 (100) | |
| CHF, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 3283 (31.0) | 4744 (100) | |
| CKD, n (%) | 1799 (48.2) | — | 2988 (49.9) | 10 584 (100) | 1926 (40.6) | |
| DM, n (%) | 1856 (49.8) | 1222 (100) | 2938 (49.1) | 10 584 (100) | 1983 (41.8) | |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 2600 (69.7) | 1010 (82.7) | 4832 (80.7) | 9365 (88.5) | 3968 (83.6) | |
| Beta blocker, n (%) | 3533 (94.7) | 1125 (92.1) | 5167 (86.3) | 6616 (62.5) | 4558 (96.1) | |
| Statin/ezetimibe, n (%) | — | — | 4131 (70.0) | — | — |
Continuous variables are presented as mean ± standard deviation, categorical variables as N (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DM, diabetes mellitus; CKD, chronic kidney disease; CHF, congestive heart failure; CVD, cardiovascular disease; n, number; SD, standard deviation; and SGLT-2, sodium–glucose cotransporter 2.
| Characteristics . | CREDENCE . | CANVAS . | DECLARE-TIMI . | EMPA-REG . | VERTIS . | DAPA-CKD . |
|---|---|---|---|---|---|---|
| SGLT-2 inhibitor | Canagliflozin | Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin | Dapagliflozin |
| Year of publication | 2019 | 2017 | 2019 | 2015 | 2020 | 2020 |
| Median follow-up period (years) | 2.6 | 2.4 | 4.2 | 3.1 | 3.0 | 2.4 |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 63.0 (9.2) | 63.3 (8.3) | 63.9 (6.8) | 63.1 (8.6) | 64.4 (8.1) | 61.8 (12.1) |
| Men, n (%) | 2907 (66.1) | 6509 (64.2) | 10 738 (62.6) | 5016 (71.5) | 5769 (70.0) | 2879 (66.9) |
| Race, n (%) | ||||||
| White | 2931 (66.6) | 7944 (78.3) | 13 653 (79.6) | 5081 (72.4) | 7240 (87.8) | 2290 (53.2) |
| Asian | 877 (19.9) | 1284 (12.7) | 2303 (13.4) | 1517 (21.6) | 498 (6.0) | 1467 (34.1) |
| Black | 224 (5.1) | 336 (3.3) | 603 (3.5) | 357 (5.1) | 235 (2.8) | 191 (4.4) |
| Other/missing | 369 (8.4) | 578 (5.7) | 601 (3.5) | 65 (0.9) | 273 (3.3) | 356 (8.3) |
| Medical history | ||||||
| CVD, n (%) | 2220 (50.4) | 6656 (65.6) | 6974 (40.6) | 7020 (100) | 8246 (100) | 1610 (37.4) |
| CHF, n (%) | 652 (14.8) | 1461 (14.4) | 1724 (10.0) | 706 (10.1) | 1958 (23.7) | 468 (10.9) |
| CKD, n (%) | 2631 (59.8) | 2039 (20.1) | 1265 (7.4) | 1819 (25.9) | 1807 (21.9) | 4304 (100) |
| DM, n (%) | 4401 (100) | 10 142 (100) | 17 160 (100) | 7020 (100) | 8246 (100) | 2906 (67.5) |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 4395 (99.9) | 8116 (80.0) | 13 950 (81.3) | 5666 (80.7) | 6686 (81.1) | 4224 (98.1) |
| Beta blocker, n (%) | 1770 (40.2) | 5421 (53.5) | 9030 (52.6) | 4554 (64.9) | 5692 (69.0) | — |
| Statin/ezetimibe, n (%) | 3036 (69.0) | 7599 (74.9) | 12868 (75.0) | 5403 (77.0) | 6790 (82.3) | 2794 (64.9) |
| Characteristics | EMPEROR REDUCED | SOLOIST-WHF | EMPEROR-PRESERVED | SCORED | DAPA-HF | |
| SGLT-2 inhibitor | Empagliflozin | Sotagliflozin | Empagliflozin | Sotagliflozin | Dapagliflozin | |
| Year of publication | 2020 | 2021 | 2021 | 2021 | 2019 | |
| Median follow-up period, (years) | 1.3 | 0.8 | 2.2 | 1.3 | 1.5 | |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 66.9 (11) | 69.5 | 71.8 (9.3) | 69 | 66.4 (10.9) | |
| Men, n (%) | 2837 (76.1) | 810 (66.2) | 3312 (55.3) | 5830 (55.1) | 3635 (76.6) | |
| Race, n (%) | ||||||
| White | 2629 (70.5) | 1139 (93.2) | 4542 (75.6) | 8749 (82.7) | 3333 (70.3) | |
| Asian | 672 (18.0) | 15 (1.2) | 824 (13.8) | 682 (6.4) | 1116 (23.5) | |
| Black | 257 (6.9) | 50 (4.1) | 258 (4.3) | 364 (3.4) | 226 (4.8) | |
| Other/missing | 172 (4.6) | 18 (1.5) | 364 (6.1) | 789 (7.5) | 69 (1.5) | |
| Medical history | ||||||
| CVD, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 9381 (88.6) | 4744 (100) | |
| CHF, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 3283 (31.0) | 4744 (100) | |
| CKD, n (%) | 1799 (48.2) | — | 2988 (49.9) | 10 584 (100) | 1926 (40.6) | |
| DM, n (%) | 1856 (49.8) | 1222 (100) | 2938 (49.1) | 10 584 (100) | 1983 (41.8) | |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 2600 (69.7) | 1010 (82.7) | 4832 (80.7) | 9365 (88.5) | 3968 (83.6) | |
| Beta blocker, n (%) | 3533 (94.7) | 1125 (92.1) | 5167 (86.3) | 6616 (62.5) | 4558 (96.1) | |
| Statin/ezetimibe, n (%) | — | — | 4131 (70.0) | — | — |
| Characteristics . | CREDENCE . | CANVAS . | DECLARE-TIMI . | EMPA-REG . | VERTIS . | DAPA-CKD . |
|---|---|---|---|---|---|---|
| SGLT-2 inhibitor | Canagliflozin | Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin | Dapagliflozin |
| Year of publication | 2019 | 2017 | 2019 | 2015 | 2020 | 2020 |
| Median follow-up period (years) | 2.6 | 2.4 | 4.2 | 3.1 | 3.0 | 2.4 |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 63.0 (9.2) | 63.3 (8.3) | 63.9 (6.8) | 63.1 (8.6) | 64.4 (8.1) | 61.8 (12.1) |
| Men, n (%) | 2907 (66.1) | 6509 (64.2) | 10 738 (62.6) | 5016 (71.5) | 5769 (70.0) | 2879 (66.9) |
| Race, n (%) | ||||||
| White | 2931 (66.6) | 7944 (78.3) | 13 653 (79.6) | 5081 (72.4) | 7240 (87.8) | 2290 (53.2) |
| Asian | 877 (19.9) | 1284 (12.7) | 2303 (13.4) | 1517 (21.6) | 498 (6.0) | 1467 (34.1) |
| Black | 224 (5.1) | 336 (3.3) | 603 (3.5) | 357 (5.1) | 235 (2.8) | 191 (4.4) |
| Other/missing | 369 (8.4) | 578 (5.7) | 601 (3.5) | 65 (0.9) | 273 (3.3) | 356 (8.3) |
| Medical history | ||||||
| CVD, n (%) | 2220 (50.4) | 6656 (65.6) | 6974 (40.6) | 7020 (100) | 8246 (100) | 1610 (37.4) |
| CHF, n (%) | 652 (14.8) | 1461 (14.4) | 1724 (10.0) | 706 (10.1) | 1958 (23.7) | 468 (10.9) |
| CKD, n (%) | 2631 (59.8) | 2039 (20.1) | 1265 (7.4) | 1819 (25.9) | 1807 (21.9) | 4304 (100) |
| DM, n (%) | 4401 (100) | 10 142 (100) | 17 160 (100) | 7020 (100) | 8246 (100) | 2906 (67.5) |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 4395 (99.9) | 8116 (80.0) | 13 950 (81.3) | 5666 (80.7) | 6686 (81.1) | 4224 (98.1) |
| Beta blocker, n (%) | 1770 (40.2) | 5421 (53.5) | 9030 (52.6) | 4554 (64.9) | 5692 (69.0) | — |
| Statin/ezetimibe, n (%) | 3036 (69.0) | 7599 (74.9) | 12868 (75.0) | 5403 (77.0) | 6790 (82.3) | 2794 (64.9) |
| Characteristics | EMPEROR REDUCED | SOLOIST-WHF | EMPEROR-PRESERVED | SCORED | DAPA-HF | |
| SGLT-2 inhibitor | Empagliflozin | Sotagliflozin | Empagliflozin | Sotagliflozin | Dapagliflozin | |
| Year of publication | 2020 | 2021 | 2021 | 2021 | 2019 | |
| Median follow-up period, (years) | 1.3 | 0.8 | 2.2 | 1.3 | 1.5 | |
| Patient characteristics | ||||||
| Age, mean (SD) (years) | 66.9 (11) | 69.5 | 71.8 (9.3) | 69 | 66.4 (10.9) | |
| Men, n (%) | 2837 (76.1) | 810 (66.2) | 3312 (55.3) | 5830 (55.1) | 3635 (76.6) | |
| Race, n (%) | ||||||
| White | 2629 (70.5) | 1139 (93.2) | 4542 (75.6) | 8749 (82.7) | 3333 (70.3) | |
| Asian | 672 (18.0) | 15 (1.2) | 824 (13.8) | 682 (6.4) | 1116 (23.5) | |
| Black | 257 (6.9) | 50 (4.1) | 258 (4.3) | 364 (3.4) | 226 (4.8) | |
| Other/missing | 172 (4.6) | 18 (1.5) | 364 (6.1) | 789 (7.5) | 69 (1.5) | |
| Medical history | ||||||
| CVD, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 9381 (88.6) | 4744 (100) | |
| CHF, n (%) | 3730 (100) | 1222 (100) | 5988 (100) | 3283 (31.0) | 4744 (100) | |
| CKD, n (%) | 1799 (48.2) | — | 2988 (49.9) | 10 584 (100) | 1926 (40.6) | |
| DM, n (%) | 1856 (49.8) | 1222 (100) | 2938 (49.1) | 10 584 (100) | 1983 (41.8) | |
| Cardiovascular medications | ||||||
| ACEI or ARB, n (%) | 2600 (69.7) | 1010 (82.7) | 4832 (80.7) | 9365 (88.5) | 3968 (83.6) | |
| Beta blocker, n (%) | 3533 (94.7) | 1125 (92.1) | 5167 (86.3) | 6616 (62.5) | 4558 (96.1) | |
| Statin/ezetimibe, n (%) | — | — | 4131 (70.0) | — | — |
Continuous variables are presented as mean ± standard deviation, categorical variables as N (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DM, diabetes mellitus; CKD, chronic kidney disease; CHF, congestive heart failure; CVD, cardiovascular disease; n, number; SD, standard deviation; and SGLT-2, sodium–glucose cotransporter 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
